Thorne HealthTech, Inc. shared significant positive findings as a result of a collaborative trial with Mayo Clinic and HealthTech Connex, Inc. – "The effects of a dietary supplement on brain function and structure in Junior A ice hockey players: a prospective randomized trial." The results are now available on Medrxiv. The double-blinded, placebo-controlled trial measured the brain function of 30 ice hockey players over the course of their season. The trial was led by Mayo Clinic's Dr. Michael Stuart who was the Principal Investigator.

The purpose of the study was to determine whether a nutritional supplement – designed to address specific mechanisms of action associated with head impact – could favorably affect those functions over the course of a hockey season. Participants went through baseline brain function testing at the beginning of the season, then consumed either Thorne's SynaQuell® or a placebo daily for the duration of their season. At the end of the study, the same brain function tests were repeated and compared.

The following are the study's findings: For all participants – those with and without a history of prior concussions – there were significant positive changes in the following when comparing the SynaQuell group to the placebo group: Brainwave latency specific selective attention and focus (N100); Visual processing speed tests. For all participants, there were trend differences when comparing the SynaQuell group to the placebo group in the following areas: Neurofilament Light (NfL) levels, which assesses neuronal damage from sports-related impacts. Processing of stimuli, which includes visual and auditory words, pictures, and gestures (N400).

In participants who had a history of concussions there were additional significant positive changes when comparing the SynaQuell group to the placebo group: Neurofilament Light (NfL) levels, which assesses neuronal damage from sports-related impacts; Processing of stimuli, which includes visual and auditory words, pictures, and gestures (N400). For all participants, the SynaQuell group showed notable improvement over the placebo group in these important measures of brain function and brain processing speed. The full study and results are expected to be available later this year.

For more details on the recently completed and ongoing clinical trials related to the effect of SynaQuell on brain function being conducted at the Mayo Clinic, visit clinicaltrials.gov #s NCT05041192 and NCT05498818.